Objective-Spleen tyrosine kinase (SYK) has come into focus as a potential therapeutic target in chronic inflammatory diseases, such as rheumatoid arthritis and asthma, as well as in B-cell lymphomas. SYK has also been involved in the signaling of immunoreceptors, cytokine receptors, and integrins. We therefore hypothesized that inhibition of SYK attenuates the inflammatory process underlying atherosclerosis and reduces plaque development.
A therosclerosis, formerly regarded as a mere lipid storage disease, is driven by a complex inflammatory and immunologic pathophysiology. Current therapeutic strategies, however, almost exclusively focus on the management of traditional cardiovascular risk factors and on revascularization procedures, lacking genuine antiinflammatory treatment options. Beyond lipid lowering, statins elicit several atheroprotective, so-called pleiotropic effects, including suppression of endothelial cell dysfunction, leukocyte recruitment, and foam cell formation, which are crucial steps in atherosclerotic plaque development. 1, 2 Several clinical trials suggested a relevant clinical benefit of these additional antiinflammatory functions of statins. 3 This has raised considerable interest in exploring ways to specifically target inflammatory processes in atherogenesis.
Spleen tyrosine kinase (SYK), a member of the nonreceptor protein tyrosine kinases, binds to the cytoplasmic tails of Fc receptors and B-cell receptors. SYK also associates with several other cell-surface receptors, such as ␤-integrins, Toll-like receptor 4, tumor necrosis factor (TNF) receptor, and the collagen receptor glycoprotein V1. 4 -9 SYK undergoes autophosphorylation and phosphorylation by Src kinases. Activated SYK phosphorylates downstream signaling proteins, controlling effects such as phagocytosis, cytokine production, cell adhesion, migration, proliferation, and differentiation 10 -13 -biological functions that figure prominently in the pathophysiology of chronic inflammatory diseases, such as atherosclerosis.
Important atheroma-associated cell types, including monocytes/macrophages, mast cells, dendritic cells, naive T cells (to a low extent), platelets, vascular endothelial cells, and smooth-muscle cells, express SYK. 4,12,14 -16 Frommhold et al demonstrated reduced postarrest spreading of SYK-deficient leukocytes to the vessel wall on stimulation with formyl-methionyl-leucyl-phenylalanine. 17 In addition, silencing of SYK by specific small interfering RNA impaired chemotaxis of RAW 264.7 cells toward CX 3 CL1 (fractalkine) 18 and attenuated lipopolysaccharide (LPS)-induced interleukin (IL)-6 and IL-8 production in THP-1 cells. 19 In light of these data, we hypothesized that SYK inhibition limits atherogenesis. Given that SYK knockout mice have a lethal phenotype, 20 we decided to use the novel, orally available SYK inhibitor fostamatinib to test the net effect of SYK inhibition on atherosclerotic plaque development in low-density lipoprotein receptor-deficient (LDLR Ϫ/Ϫ ) mice. Fostamatinib is the prodrug of R406, a specific ATP-competitive SYK inhibitor. 21 Fostamatinib has already been successfully tested in rheumatoid arthritis, immune thrombocytopenic purpura, and B-cell lymphomas in both rodent models and in clinical phase II trials in humans. [22] [23] [24] [25] [26] 
Methods
A detailed description of all methods is available in the supplemental material, available online at http://atvb.ahajournals.org.
Murine Atherosclerosis Model and SYK Inhibition
Seven-week-old LDLR Ϫ/Ϫ mice consumed high-cholesterol diet (HCD), HCD supplemented with the SYK inhibitor fostamatinib (Rigel Pharmaceuticals, Inc., South San Francisco, CA, USA) at concentrations of 0.5 and 2.0 g fostamatinib per kilogram HCD (similar to previous murine studies 27, 28 ) , or low-cholesterol diet ad libitum. Fostamatinib without carrier was incorporated into HCD by Ssniff GmbH (Soest, Germany), which also provided plain HCD (modified D1208). This route of administration achieved plasma levels of the drug also observed in humans receiving the standard dosage of 50 mg or 150 mg fostamatinib BID, as seen in a kinetic study performed in LDLR Ϫ/Ϫ mice by us, upfront (see Supplemental Figure I ). After 16 weeks, mice were euthanized and aortas were prepared and analyzed as described previously. 29
Cytokine Challenge Model
Mice consumed HCD with or without 2.0 g fostamatinib per kilogram HCD for 10 days before intraperitoneal challenge with TNF␣ (10 g/kg) or LPS (1 mg/kg). Subsequently, plasma levels of inflammatory cytokines were measured by cytometric bead array, and peripheral blood cells were analyzed by fluorescence-activated cell sorting as described previously. 30
Murine Peritonitis
Leukocyte invasion into the peritoneal cavity was tested by peritoneal instillation of thioglycollate in mice fed HCD with or without 2.0 g fostamatinib per kilogram HCD for 10 days, as described previously. 29 
Intravital Microscopy
Mice consumed HCD with or without 2.0 g fostamatinib per kilogram HCD for 10 days before intraperitoneal challenge with TNF␣ (10 g/kg). Preparation of the cremaster and analysis of rolling and adhering leukocytes in venules of 30 to 50 m was performed by blinded investigators as described previously. 30 
Cell Isolation and Culture
Murine endothelial cells and bone marrow-derived macrophages (BMMCs) were isolated and cultured, as described previously. 29 Raw 264.7 cells were cultured in Dulbecco's modified Eagle's mediumϩ5% fetal calf serum. The active metabolite R406 of the prodrug fostamatinib was used for SYK inhibition in vitro and the solvent dimethyl sulfoxide as control.
Immunoblotting and Immunoprecipitation
Western blotting was performed as described previously. 30, 31 Primary antibodies included anti-SYK (Cell Signaling Technology, 4D10), anti-SYK (Cell Signaling, #2712), anti-phospho-SYK Tyr525/526 (Cell Signaling), and anti-pTyr 4G10 (Millipore). SYK phosphorylation was determined by immunoprecipitation for SYK and subsequent blotting for phosphotyrosine residues as described previously. 26 
Flow Cytometry
Flow cytometry was performed as previously described. 32 Antibodies included anti-CD11b-fluorescein isothiocyanate, anti-CD115phycoerythrin (PE), anti-Gr-1-allophycocyanin, anti-CD3allophycocyanin, anti-CD4-Alexa, anti-CD8-PE, anti-CD20-PE, and anti-F4/80-PE.
Inflammatory Cytokine and Chemokine Quantification
Inflammatory cytokines in supernatants of cell cultures and plasma were quantified by commercially available ELISA kits (DuoSet, R&D Systems) and multiplex assays (Luminex, Rigel Pharmaceuticals, Inc, and BD Bioscience) according to the manufacturers' instructions.
Quantitative Reverse Transcription-Polymerase Chain Reaction
Total RNA was isolated from aortas according to a modified Trizol protocol and transcribed to cDNA, and targets were analyzed by quantitative reverse transcription-polymerase chain reaction as described previously. 30
Scratch Assay
BMMCs were cultured in fetal calf serum-coated 6-well plates, and we obtained Ϸ80% confluence. Following a marking line, cells were scraped with a 1000-L pipette tip. Nonadherent cells were washed off. Images were taken before cells were incubated at 37°C in growth medium. After 24 hours, images of the same regions were taken again, and numbers of cells that had migrated into the denuded zones were counted by blinded investigators.
Apoptosis, Cytotoxicity, and Proliferation Assay
Terminal deoxynucleotidyl transferase dUTP nick-end labeling staining of frozen sections of aortic roots was performed as previously described. 31 Caspase 3/7 activity in BMMCs cultured with R406 or vehicle for 24 hours was determined by fluorometric assay kit Apo-ONE (Promega), and cytotoxicity was determined by the fluorometric assay kit CytoTox-ONE (Promega), according to the manufacturer's instructions. Proliferation was determined by 5-bromo-2Ј-deoxyuridine incorporation and colorimetric ELISA (Roche).
Statistical Analysis
Data are expressed as meanϮSEM of absolute or normalized values. Groups were compared using the Student t test. A value of PՅ0.05 was considered significant.
Results

Atherosclerotic Lesions Overexpress Activated SYK, and Fostamatinib Inhibits SYK Activation In Vivo
Although atheroma-associated cell types are known to express SYK, we investigated expression of its phosphorylated, biologically active form in atherosclerotic lesions. Human carotid arterial tissue with stable or unstable atherosclerotic lesions, as determined by histological criteria, 33 contained more phosphorylated SYK than healthy arterial tissue, as determined by immunoprecipitation ( Figure 1A) . Similarly, SYK phosphorylation (Tyr352) increased in murine atherosclerotic lesions obtained from LDLR Ϫ/Ϫ mice consuming HCD for 16 weeks compared with arterial sections from control mice consuming normal chow. High magnification revealed abundant expression in macrophage-rich areas ( Figure 1B) .
To test the hypothesis that SYK inhibition may limit atherogenesis in vivo, the oral SYK inhibitor fostamatinib was incorporated into HCD at 0.5 or 2.0 g fostamatinib per kilogram HCD (Ssniff GmbH). An initial kinetic study confirmed bioavailability of the drug in LDLR Ϫ/Ϫ mice (Supplemental Figure I) and resulted in levels similar to those observed in humans receiving 50 mg and 150 mg fostamatinib BID, respectively 22 ( Figure 1C ). Furthermore, fostamatinib abrogated LPS (1 mg/kg)-induced SYK phosphorylation at the autophosphorylation site Tyr525/526 in mice, demonstrating effective SYK inhibition in vivo ( Figure 1D ).
The SYK Inhibitor Fostamatinib Attenuates Atherosclerosis in Mice
On 16 weeks of feeding, fostamatinib dose-dependently reduced atherosclerotic lesion sizes in aortic roots and arches by up to 59Ϯ6% and 68Ϯ14%, respectively (Figure 2A and 2B). All mice appeared healthy and had no obvious abnormalities. Weights of fostamatinib-treated mice did not differ from those of HCD controls at the end of the study. Cholesterol and triglyceride levels did not differ at baseline between the 2 groups, but triglyceride levels were slightly higher in fostamatinib-treated animals after HCD (Supplemental Table I ). Fostamatinib normalized HCD-induced monocytosis and neutrophilia and attenuated T-and B-lymphocyte numbers (Supplemental Figure II) .
Fostamatinib Favorably Alters Plaque Composition and Inflammation
Most prominently, plaques from fostamatinib-treated animals contained significantly fewer macrophages than those from respective untreated HCD control animals, whereas the amount of collagen and smooth-muscle cells increased and lipid and T-helper-cell content did not change ( Figure  3A and B ). Furthermore, plaques from fostamatinib-treated mice expressed less IL-6 and, by trend, also less IL-12 and TNF␣ ( Figure 3C ), whereas the expression of monocyte chemotactic protein-1, keratinocyte-derived chemokine, and RANTES remained unaffected (Supplemental Figure  III) . In line with these findings, endothelial cells stimulated with TNF␣ and LPS in vitro expressed lower were stained with antiphospho-SYK (Tyr352) antibody. SYK phosphorylation was quantified digitally and is displayed as meanϮSEM. Images of representative sections are displayed on the left including higher magnification (ϫ40) of a lesion. Scale barsϭ1000 m (left two panels) and 100 m (right panel). C, R406 plasma levels were measured in blood samples collected the evening before euthanization, after 16 weeks of HCD supplemented with 0.5 g fostamatinib (fosta) (nϭ9) and 2.0 g fostamatinib per kilogram HCD (nϭ14). D. Low-density lipoprotein receptor-deficient mice consumed either HCD or HCD supplemented with 2.0 g fostamatinib per kilogram HCD for 10 days. Blood cell lysates were analyzed for SYK phosphorylation at the autophosphorylation site (Tyr525/526) and for total SYK expression by Western blot before and 20 minutes after stimulation with 1 mg/kg lipopolysaccharide (LPS) intraperitoneally.
amounts of IL-6 on coincubation with R406, whereas no difference was seen for monocyte chemotactic protein-1 expression (Supplemental Figure IV) . Systemically, serum levels of IL-1␤, IL-6, IL-10, IL-12, interferon-␥, macrophage colony-stimulating factor (M-CSF), vascular endothelial growth factor, macrophage inflammatory protein-2, monocyte chemotactic protein-1, and keratinocyte-derived chemokine remained very low in general and did not differ among the 4 study groups after 16 weeks of diet (data not shown). However, when mice were challenged with intraperitoneal injections of TNF␣ (10 g/kg) or LPS (1 mg/kg), systemic cytokine and chemokine levels increased significantly. Under these conditions, fostamatinib attenuated TNF␣-induced interferon-␥ and LPS-induced IL-12 and interferon-␥ levels, as well as TNF␣ and LPS-induced leukocyte recruitment to the blood pool. Although overall monocyte counts did not differ between the 2 groups, fostamatinib treatment caused a significant shift from the proinflammatory Gr-1 high monocyte subtype to the rather antiinflammatory Gr-1 low subtype (Supplemental Figure V) .
Fostamatinib Impairs Inflammatory Cell Recruitment to the Endothelium
Given the markedly reduced macrophage content in atherosclerotic lesions of fostamatinib-treated mice, we explored a putative effect of fostamatinib on inflammatory cell recruitment. Therefore, mice consuming HCD or HCD supplemented with 2.0 g fostamatinib per kilogram HCD were subjected to intravital microscopy. Fostamatinib significantly reduced both rolling and adhesion of inflammatory cells to the endothelium of cremasteric muscle venules ( Figure 4C ). Of note, in contrast to the long-term atherosclerosis study, overall leukocytes numbers were not affected by fostamatinib treatment for 10 days, ruling out the possibility that a decrease in systemic leukocyte numbers accounted for the reduced recruitment of inflammatory cells observed ( Figure  4B ). Adhesion molecules regulate inflammatory cell recruitment. Therefore, we evaluated intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression in sections of the aortic roots of mice of our atherosclerosis study. Interestingly, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression along the endothelial lining of plaques was significantly reduced in fostamatinib-treated animals compared with the respective controls ( Figure 4A ).
Fostamatinib Reduces Migration of Inflammatory Cells
To test whether fostamatinib also affects migration of inflammatory cells, we induced peritonitis in mice that received HCD or HCD supplemented with fostamatinib for 10 days by instillation of thioglycollate. Indeed, mice treated with fostamatinib accumulated significantly fewer leukocytes, both neutrophils and macrophages, in the peritoneal cavity compared with the respective control animals ( Figure 5C and 5D ). Interestingly, already baseline cell counts in the peritoneal lavage were reduced before challenge with thioglycollate in animals treated with fostamatinib for 10 days, whereas systemic leukocyte counts were not influenced. This finding was mainly due to lower numbers of F4/80 ϩ resident macrophages in fostamatinib-treated mice, confirming the defective macrophage recruitment we observed in atherosclerotic plaques of fostamatinib-treated animals ( Figure 5A and 5B). Similarly, in vitro, the number of BMMCs migrating into the denuded zone was reduced by half in the presence of R406 in a scratch wound assay, corroborating that fostamatinib limits the migratory capacity of inflammatory cells ( Figure 5E ).
Fostamatinib Impairs Macrophage Differentiation and Survival
Because numbers of macrophages in atherosclerotic lesions of fostamatinib-treated mice were markedly reduced in our study, we also tested whether SYK inhibition by fostamatinib affected macrophage survival. Terminal deoxynucleotidyl transferase dUTP nick-end labeling staining of frozen sections of aortic roots revealed a slight but nonsignificant increase in apoptotic cell numbers in lesions of fostamatinibtreated mice compared with the respective controls ( Figure  6A) . Similarly, BMMCs cultured in serum-free medium in the presence or absence of the SYK inhibitor R406 for 24 hours showed a slight but nonsignificant increase in caspase 3/7 activity ( Figure 6B ). Release of lactate dehydrogenase by cultured BMMCs ( Figure 6C ) and proliferation of the murine monocytic cell line Raw 264.7 ( Figure 6D) were not altered by treatment with SYK inhibitor R406, indicating that the drug effects observed were not due to drug cytotoxicity. Because SYK has been reported to be involved in M-CSF receptor signaling, 34 macrophages were cocultured with M-CSF in the presence or absence of SYK inhibitor R406. As expected, vehicle-treated BMMCs were rescued from apoptosis when M-CSF was added to the medium. However, caspase activity in macrophages treated with high dose R406 remained elevated despite M-CSF treatment, and low-dose R406 had an intermediate effect ( Figure 6B ). These data suggest that SYK inhibition by fostamatinib limits M-CSFinduced macrophage survival. Because M-CSF serves as the main stimulus for monocytes/macrophage differentiation, we investigated the differentiation of isolated mononuclear bone marrow cells to BMMCs under the influence of M-CSF over 6 days in the presence or absence of SYK inhibitor R406. On M-CSF stimulation, adhering cells develop into mature macrophages overexpressing F4/80, unlike their early precursors. 35 When we cocultured cells with SYK inhibitor R406, both the percentage of F4/80positive macrophages and the expression of F4/80 as a maturation marker were reduced, as determined by fluorescence-activated cell sorting ( Figure 6E ). We therefore concluded that SYK inhibition significantly impaired monocyte to macrophage differentiation.
Discussion
The aim of our study was to explore the effect of SYK inhibition on atherosclerosis. Our hypothesis of an antiatherogenic effect was based on the literature published on SYK and SYK inhibition in chronic inflammatory diseases. 4, [21] [22] [23] 36 The detection of SYK phosphorylation in atherosclerotic lesions in mice and humans encouraged us to conduct an atherosclerosis mouse study with the orally available SYK inhibitor fostamatinib.
HCD induces atherosclerotic lesions in LDLR Ϫ/Ϫ mice. 37 Fostamatinib dose-dependently reduced lesion size in our study. Beyond a mere reduction in size, lesions of fostamatinib-treated animals contained fewer macrophages. At the same time, collagen and smooth-muscle cell content was increased. These are features attributed to more stable plaques in humans. 33 Hypercholesterolemia is known to increase numbers of neutrophils and monocytes in blood. 38 Mechanisms proposed include reduction of cell apoptosis, increased proliferation, and impaired Ly-6C high Gr-1 high to Ly-6C low Gr-1 low monocyte conversion. Although cholesterol levels were similar in the HCD and HCD supplemented with fostamatinib feeding groups, fostamatinib intake reduced overall leukocyte and particularly monocyte and neutrophil counts to levels measured in mice consuming normal chow (low-cholesterol diet), an antiinflammatory effect that may contribute to the smaller and less inflamed atherosclerotic lesions observed in fostamatinib-treated animals. Also, numbers of T-and B-lymphocytes were lower in mice receiving HCD supplemented with 2.0 g fostamatinib per kilogram HCD; thus, we cannot rule out that immunosuppression contributes to the observed phenotype. However, this is not very likely, because numbers of both T and B cells were reduced in fostamatinib-treated mice, and these cell types have been suggested to have opposing effects on atherogenesis. 39, 40 Moreover, even if mild immunosuppression plays a role, this may not be detrimental, because fostamatinib has been well tolerated in clinical trials, and immunosuppression by other agents (such as methotrexate) has recently been proposed as a therapeutic strategy in patients with coronary heart disease. 41 Inflammatory cell recruitment to the vessel wall is a pivotal step during the development of atherosclerotic lesions and progressive during the disease's course. 42 It is a multistep process involving rolling, adhesion, and migration of cells. 43 To gain further mechanistic insight into how fostamatinib modulates plaque growth, we tested whether it affects either of these functions. Interestingly, fostamatinib attenuated both rolling and adhesion in cremaster muscle venules, as well as accumulation of inflammatory cells in the peritoneal cavity in thioglycollateelicited peritonitis. Accordingly, SYK inhibition impaired migration of BMMCs into a scratch wound assay in vitro.
Our results corroborate the involvement of SYK in mediating leukocyte invasion to sites of inflammation and suggest that inhibition of leukocyte recruitment may be the principal mode of action of fostamatinib, resulting in decreased atherosclerosis development in mice. Mechanistically, SYK is known to be crucially involved in downstream signaling of P-selectin glycoprotein ligand-1, the main ligand for selectin-mediated cell capturing and rolling on the endothelium, and in selectin-mediated integrin activation. 44, 45 Integrins bind to the extracellular matrix and to intercellular adhesion molecule and vascular cell adhesion molecule for firm cell adhesion. SYK also participates in integrin signaling pathways leading to cell activation. 46 These attributes may well explain the reduced leukocyte recruitment observed in this study. Beyond that, expression of the adhesion molecules intercellular adhesion molecule and vascular cell adhesion molecule on the surface of atherosclerotic lesions were reduced in fostamatinibtreated mice in our study. Our data are in line with previous reports demonstrating reduced formyl-methionyl-leucylphenylalanine-induced neutrophil migration in the presence of the SYK inhibitor piceatannol in vitro and impaired leukocyte arrest, postarrest flattening, and extravasation in formylmethionyl-leucyl-phenylalanine-superfused cremaster muscle venules in SYK Ϫ/Ϫ bone marrow chimeras in vivo. 17, 36 Schymeinsky et al reported impaired neutrophil infiltration in excisional wounds in SYK-deficient chimeras, again demonstrating the in vivo relevance of SYK for leukocyte recruitment to sites of inflammation. 47 Besides attenuating leukocyte recruitment to atherosclerotic lesions, our data suggest that SYK inhibition may also impair macrophage survival and differentiation, most likely because of interference with M-CSF signaling because SYK is known to be activated by binding of M-CSF to its receptor c-fms. 34 This could also contribute to the decreased atherosclerosis observed in fostamatinib-treated mice.
Fostamatinib has been studied extensively in rodent models of chronic inflammatory diseases, such as arthritis and asthma, and has been shown to reduce inflammatory cytokine and chemokine expression in these models. Previously reported target genes include IL-1␤, IL-6, TNF␣, keratinocytederived chemokine, and monocyte chemotactic protein-1. 22, 23 Several of these genes also play a pivotal role in the inflammatory processes underlying atherosclerosis and its complications. 48, 49 We did not detect systemic regulation of inflammatory cytokines or chemokines in our study animals, but SYK inhibition by fostamatinib downregulated the expression of inflammatory gene products both in atherosclerotic aortas in vivo and in vascular endothelial cells in vitro when stimulated with TNF␣ or LPS. When mice were systemically challenged with TNF␣ or LPS, IL-12 and interferon-␥ levels were decreased by fostamatinib treatment. Both TNF receptor and Toll-like receptor 4 are activated in atherosclerosis, 50, 51 and SYK associates with these receptors. 7, 8, 52 These data suggest that SYK inhibition by fostamatinib enfolds antiinflammatory effects even beyond inhibition of inflammatory cell recruitment to the blood pool and sites of inflammation.
We demonstrated here that long-term treatment with the SYK inhibitor fostamatinib attenuates plaque development in mice. Mechanistically impaired macrophage recruitment to the vessel wall, reduced macrophage survival, and a blunted inflammatory response most likely underlie these findings.
With fostamatinib having already been tested in phase II clinical trials in humans with arthritis and lymphomas, our study may help to open up yet another important field of application: cardiovascular diseases.
